Nivolumab and Relatlimab (Opdualag)
These drugs target and inhibit immune checkpoints PD-1 and LAG-3, these are proteins that are present on cells of the immune system (called T cells), that normally help keep these cells from attacking other cells in the body. By blocking PD-1 and LAG-3, this drug boosts the immune response against melanoma cells. This can often shrink tumours and help people live longer.
- For more information visit Bristol Myers Squibb Canada
Side Effects
The most common side effects from this drug include fatigue, diarrhea, skin rash, and itching. Serious side effects seem to happen more often with this drug than with the PD-1 inhibitors. Like the PD-1 inhibitors, this drug can cause the immune system to attack other parts of the body, which can lead to serious problems in the intestines, liver, hormone-making glands, nerves, skin, eyes, or other organs. In some people these side effects have been fatal.
It’s very important to report any new side effects during or after treatment to your health care team promptly.
Watch Now – Video on the side effects of Immunotherapies
Provincial Funding Summary
Eligibility is determined by a melanoma specialist and or medical oncologist. OPDUALAG is to be covered to treat patients aged 12 years or older who: have a histologically confirmed diagnosis of unresectable stage III or stage IV (metastatic) melanoma and have not received prior systemic therapy for advanced melanoma.
View Summary PDF (excludes Quebec)